RMD Open

Article	Citations
Associations of infection burden with Kawasaki disease in a population-based setting during 30 years	130
Impact of Sjögren’s disease on quality of sexual life using the Qualisex score	111
Incidence of collagen-induced arthritis is elevated by a high-fat diet without influencing body weight in mice	100
Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study	92
Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy	76
Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: long-term safety and follow-up	75
Whipple’s disease: a rare cause of sacroiliitis	64
Effects of ibuprofen on gene expression in chondrocytes from patients with osteoarthritis as determined by RNA-Seq	60
Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study	58
Classification of rheumatoid arthritis: is it time to revise the criteria?	53
Window of opportunity in psoriatic arthritis: the earlier the better?	53
Exploring complement biomarkers in suspected axial spondyloarthritis	52
Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study	51
Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis	51
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study	47
Course of paediatric ANCA-associated glomerulonephritis: advocating for an age-inclusive approach	47
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis	46
Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis	46
Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination	45
Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort stud	44
Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: a nationwide, population-based cohort study in Taiwan	43
Maternal and infant outcomes in pregnancies of women with axial spondyloarthritis compared with matched controls: results from nationwide health insurance data	43
Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort	43
No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry	42
Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts	42

COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2	41
Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database	39
Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases	36
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy	33
Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study	33
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination	33
Fibromyalgia and mortality: a systematic review and meta-analysis	32
Impact of sex on spinal radiographic progression in axial spondyloarthritis: a longitudinal Swiss cohort analysis over a period of 10 years	32
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism	31
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan	30
Good construct validity of the CT Syndesmophyte Score (CTSS) in patients with radiographic axial spondyloarthritis	29
Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations	29
Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease	29
Use of non-surgical treatments on the journey to knee replacement in patients with knee osteoarthritis: a 10-year population-based case–control study	29
A rare side effect of methotrexate therapy: drug-induced osteopathy with multiple fractures of the lower limb	28
Predictive utility of ANCA positivity and antigen specificity in the assessment of kidney disease in paediatric-onset small vessel vasculitis	27
Application of EULAR and European Society of Cardiology recommendations with regard to blood pressure and lipid management in antiphospholipid syndrome	27
‘Gout was like the boss’. A qualitative study exploring the impact of gout on employment	27
Impact of ultrasound limitation to assess aortitis in patients with giant cell arteritis: comparative study with FDG-PET/CT	27
Severe case of rhabdomyolysis following jellyfish envenomation in the Mediterranean Sea	26
Time trends in the burden of autoimmune diseases across the BRICS: an age–period–cohort analysis for the GBD 2019	26
Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease	25
Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study	24
It is not just about sex: viewpoints of men with inflammatory arthritis on the overall impact of the disease on their sexual health	24
Developing evidence-based patient-focused learning materials to support health behaviour change for people living with psoriatic arthritis	24
Associations of pain sensitisation with tender and painful joint counts in people with hand osteoarthritis: results from the Nor-Hand study	24
Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis	24
Allele-specific protein binding within theCD40locus in human synovial fibroblasts and immune cells	23
Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomes	23
Case report: crowned dens syndrome in a patient with seronegative rheumatoid arthritis	23
Urinary methotrexate dosage in rheumatoid arthritis, in patients treated for at least 6 months: a potential marker of adherence	23
Involving patients as research partners in research in rheumatology: a literature review in 2023	23
Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial	23
Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects	22
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort	22
Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice	22
Preconception clinical factors related to adverse pregnancy outcomes in patients with systemic lupus erythematosus or primary Sjögren’s syndrome: a retrospective cohort study	22
Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry	22
The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arth	22
Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis	22
Large language model-driven sentiment analysis for facilitating fibromyalgia diagnosis	22
The mSQUASH is a feasible and valid measurement tool to uniformly assess daily physical activity in patients with rheumatic diseases	22
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cr	21
Antirheumatic treatment, disease activity and risk ofStaphylococcus aureusbacteraemia in rheumatoid arthritis: a nationwide nested case–control study	21
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 tri	21
Increased prevalence of hearing loss, tinnitus and sudden deafness among patients with Sjögren’s syndrome	21
Dynamic change in red cell distribution width as a predictor for short-time mortality in dermatomyositis-associated rapid progressive interstitial lung disease	21
Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLO	20
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis	20
Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce	20

Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupu	20
Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs	20
Missing data in randomised controlled trials of rheumatoid arthritis drug therapy are substantial and handled inappropriately	20
PD-1/PD-L1 governed cross-talk of exhausted CD8+T and memory B cells in systemic lupus erythematosus	20
DWI scrolling artery sign for the diagnosis of giant cell arteritis: a pattern recognition approach	20
Association between hyperuricaemia and hand osteoarthritis: data from the Xiangya Osteoarthritis Study	19
Metabolomic profiles, polygenic risk scores and risk of rheumatoid arthritis: a population-based cohort study in the UK Biobank	19
Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results	19
Concordance and agreement between different activity scores in polymyalgia rheumatica	19
Reactive arthritis after SARS-CoV-2 infection	19
Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status	19
Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies	19
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider	19
Development of a web-based ecological momentary assessment tool to measure day-to-day variability of the symptoms in patients with Sjögren’s disease	18
Two-year clinical follow-up enhances the diagnosis of early-stage hip osteoarthritis: data from check cohort	18
Glucocorticoid trajectories over 2 years in patients with rheumatoid arthritis in a real-life setting	18
Depression, anxiety and cognitive function in persons with inflammatory rheumatic diseases: cross-sectional results from the German National Cohort (NAKO)	18
Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases	18
Hyperactivation and altered selection of B cells in patients with paediatric Sjogren’s syndrome	18
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch fr	18
Comorbidity burden on mortality in patients with systemic sclerosis	18
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)	18
Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?	18
Fluorescence optical imaging: ready for prime time?	18
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis	18
Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study	18
Altered dynamic functional network connectivity in rheumatoid arthritis associated with peripheral inflammation and neuropsychiatric disorders	17
Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA	17
Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study	17
Burden of coronary artery calcification in ANCA-associated vasculitis	17
Impact of an intervention for osteoarthritis based on exercise and education on metabolic health: a register-based study using the SOAD cohort	17
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritis	17
Disease activity trajectories from childhood to adulthood in the population-based Nordic juvenile idiopathic arthritis cohort	17
Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab	17
Reference intervals of work ability and productivity loss and their use in patients with inflammatory rheumatic and musculoskeletal diseases	17
Impact of inflammation on cognitive function in patients with highly inflammatory rheumatoid arthritis	17
Associations of sociodemographic, clinical factors and HLA-B alleles with enthesitis and peripheral arthritis in patients with ankylosing spondylitis	17
Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study	17
EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future	17
Infliximab use and cervical spine deformity in patients with rheumatoid arthritis	17
Artificial intelligence in rheumatology research: what is it good for?	17
Correction: Multicentrer study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results	16
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study	16
Correction: Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice	16
Correction: Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculos	16
Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider	16
Correction: Disparities in health care in psoriatic arthritis: an analysis of 439 patients from 13 countries	16
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study	16
Correction: Significance of structural changes in the axial skeleton in patients with axial spondyloarthritis: how important are lesions in the sacroiliac joint?	16
Correction: Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarthritis	16
Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone	16
Polygenic Risk Score Predicts Earlier-Onset Adult Systemic Lupus Erythematosus and First-Year Renal Diseases in a Taiwanese Cohort	16
Correction: In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study	16
National burden of rheumatoid arthritis in Canada, 1990–2019: findings from the Global Burden of Disease Study 2019 – a GBD collaborator-led study	15
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2	15
Mechanisms of action of therapeutic exercise for knee and hip OA remain a black box phenomenon: an individual patient data mediation study with the OA Trial Bank	15
Spondyloarthritis in inflammatory bowel disease cohorts: systematic literature review and critical appraisal of study designs	15
Trends in amyloidosis in spondyloarthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999–2015)—TREND-EspA study	15
Immunoglobulins G from Patients with Systemic Sclerosis Modify the Molecular Signatures of Endothelial Cells	15
Pain in autoimmune inflammatory myopathies: a scoping review	15
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study	15
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination	15
Sex differences in cytokines and adipokines in obese patients with PsA and controls undergoing a weight loss intervention	15
Pollutants: a candidate as a new risk factor for osteoarthritis—results from a systematic literature review	15
Social media in advancing equity and collaboration in rheumatology: the CORDIALITY review	15
Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study	14
Effect of nurse-led care on outcomes in patients with ACPA/RF-positive rheumatoid arthritis with active disease undergoing treat-to-target: a multicentre randomised controlled trial	14
Associations between markers of inflammation and altered pain perception mechanisms in people with knee osteoarthritis: a systematic review	14
Correction: comparison of active tuberculosis occurrence associated with janus kinase inhibitors and biological DMARDs in rheumatoid arthritis	14
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study	14
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry	14
EducAR: implementing a multicomponent strategy to improve therapeutic adherence in rheumatoid arthritis	14
Suprascapular nerve block for the treatment of adhesive capsulitis: a randomised double-blind placebo-controlled trial	14
Holistic approaches in systemic lupus erythematosus: do physicians avoid addressing difficult-to-treat but highly relevant symptoms?	14
CT-like images of the sacroiliac joint generated from MRI using susceptibility-weighted imaging (SWI) in patients with axial spondyloarthritis	14
Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis	14
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks o	14
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study	14
Correction: Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis	14
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study	13

Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation	13
Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritis	13
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis	13
Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome	13
Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany	13
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: a systematic review following COSMIN guidelines	13
Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings	13
White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms	13
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomis	13
New animal model of chronic gout reproduces pathological features of the disease in humans	13
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study a	13
Epidemiology and clinical characteristics of biopsy-confirmed adult-onset IgA vasculitis in southern Sweden	13
Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study	13
Safety, patient acceptance and diagnostic accuracy of ultrasound core needle biopsy of parotid or submandibular glands in primary Sjögren’s syndrome with suspected salivary gland lymphoma	13
Impact of apremilast on quality of life in Behçet’s syndrome: analysis of the phase 3 RELIEF study	13
Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON	13
Personalised care packages for people with rheumatoid arthritis: a mixed-methods study	13
Validity of the EULAR recommendations on the use of ultrasound in the diagnosis of giant cell arteritis	13
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index	13
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors	13
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study	12
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases	12
Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab	12
Case of new-onset scleromyxoedema–scleroedema spectrum disorder in a patient with CLL	12
Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network	12
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance	12
Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews	12
High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex	12
Use and detailed metric properties of patient-reported outcome measures for rheumatoid arthritis: a systematic review covering two decades	12
Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit	12
Fcγ-receptor-IIIA bioactivity of circulating and synovial immune complexes in rheumatoid arthritis	12
Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloa	12
Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study	12
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider	12
Large language models for accurate disease detection in electronic health records: the examples of crystal arthropathies	12
History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis	12
SAPHO syndrome can cause sausage finger lesions	12
Engagement and attrition with eHealth tools for remote monitoring in chronic arthritis: a systematic review and meta-analysis	12
Association between resolution of MRI-detected inflammation and improved clinical outcomes in axial spondyloarthritis under long-term anti-TNF therapy	12
Characteristics and outcome of critically ill patients with systemic rheumatic diseases referred to the intensive care unit	11
Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition	11
Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entry	11
Dysregulated long non-coding RNA in Sjögren’s disease impacts both interferon and adaptive immune responses	11
Need and value of targeted immunosuppressive therapy in giant cell arteritis	11
Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies	11
Are poor prognostic factors a realistic basis for treatment decisions in patients with rheumatoid arthritis? Lessons from the IMPROVED study	11
Patterns of clinical joint inflammation in juvenile idiopathic arthritis	11
Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarthritis	11
Comparison between primary Sjögren’s disease patients with high or low level of dryness	11
Impact of rheumatoid arthritis and methotrexate on pregnancy outcomes: retrospective cohort study of the Italian Society for Rheumatology	11
Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data	11
Recurrence of axial spondyloarthritis among first-degree relatives in a prospective 35-year-follow-up family study	11
Body composition is associated with changes in health-related quality of life in patients with knee and/or hip osteoarthritis	11
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA	11
Risk of cancer in Korean patients with psoriatic arthritis: a nationwide population-based cohort study	11
Inflammation in the posterior elements, in particular the facet joint and facet joint ankylosis over 2-year follow-up in radiographic axial spondyloarthritis	11
Learning imaging in axial spondyloarthritis: more than just a matter of experience	11
Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases	11
High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort	11
Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden	11
Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis	11
Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening	11
Correction: miRNAs as potential biomarkers for subclinical atherosclerosis in sjögren’s disease	11
Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database	11
Autoantibody status according to multiparametric assay accurately estimates connective tissue disease classification and identifies clinically relevant disease clusters	11
Machine learning identifies risk factors associated with long-term opioid use in fibromyalgia patients newly initiated on an opioid	11
Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System	11
Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis	10
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years	10
Are cleaning activities a source of exposure to crystalline silica in women with rheumatoid arthritis? A case–control study	10
Gut microbiota in very early systemic sclerosis: the first case-control taxonomic and functional characterisation highlighting an altered butyric acid profile	10
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib	10
Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review	10
Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid ar	10
Tolerability of low to moderate biomechanical stress during leisure sport activity in patients with psoriasis and psoriatic arthritis	10
Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis	10
Biomechanical determinants of rheumatoid arthritis severity and excess cardiovascular disease: common origins of two complex diseases	10
Eosinopenia and routine inflammatory biomarkers are helpful for the diagnosis of infection in patients treated with IL-6 pathway antagonists	10
Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment	10
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression	10
Identification of patient endotypes and adalimumab treatment responders in axial spondyloarthritis using blood-derived extracellular matrix biomarkers	10
Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts	10
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS)	10
Association of aFAM13Avariant with interstitial lung disease in Japanese rheumatoid arthritis	10
Suitability for e-health of non-pharmacological interventions in connective tissue diseases: scoping review with a descriptive analysis	9
Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes	9
Ultrasound assessment of degenerative muscle sarcopenia: the University of Barcelona ultrasound scoring system for sarcopenia	9
Different disease activity trajectories in early axial spondyloarthritis lead to significantly different long-term outcomes: a trajectory-based analysis of the DESIR cohort over 10 years	9
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry	9
Impact of assessing patient-reported outcomes with mobile apps on patient–provider interaction	9
Dissecting signalling pathways associated with intrarenal synthesis of complement components in lupus nephritis	9
The effect of rituximab on patient reported outcomes in the preclinical phase of rheumatoid arthritis: 2 year data from the PRAIRI study	9
EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative	9
Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis	9
Endothelial dysfunction and increased carotid intima–media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors	9